<DOC>
	<DOCNO>NCT01108107</DOCNO>
	<brief_summary>This study investigate - effect preoperative combination chemotherapy patient locally advanced colon cancer mutation KRAS , BRAF PIK3CA gene - effect preoperative combination chemotherapy combination biological treatment patient without mutation KRAS , BRAF PIK3CA gene .</brief_summary>
	<brief_title>Neoadjuvant Treatment Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically verify locally advanced T3 T4 colon cancer assess CT scan Analysis KRAS , BRAF , PIK3CA Age ≥18 år Performance status ≤ 2 Hematology ANC ≥ 1.5x10^9/l . Thrombocytes ≥ 100x10^9/l . Biochemistry Bilirubinaemia ≤ 3 x UNL . ALAT ≤ 5 x UNL Consent translational research Fertile woman must present negative pregnancy test use secure birth control 3 month treatment . Written orally inform consent . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment , active severe infection concurrent disease . Peripheral neuropathy NCI grade &gt; 1 Other malignant disease within 5 year prior enrollment , except basal cell squamous carcinoma skin cervical carcinomainsitu Other investigational treatment within 30 day prior treatment start History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Bleeding tumor Hypersensitivity one substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>Neoadjuvant treatment</keyword>
	<keyword>KRAS mutation</keyword>
	<keyword>BRAF mutation</keyword>
	<keyword>PIK3CA mutation</keyword>
	<keyword>Possibly avoid chemotherapy operation</keyword>
</DOC>